Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oculis Holding AG OCS

Healthcare
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody... see more

Recent & Breaking News (NDAQ:OCS)

Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

GlobeNewswire April 8, 2024

Oculis to Participate at Upcoming April Investor Conferences

GlobeNewswire April 4, 2024

Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress

GlobeNewswire March 18, 2024

Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments

GlobeNewswire February 28, 2024

Oculis to Present at Upcoming February Investor Conferences

GlobeNewswire January 29, 2024

Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024

GlobeNewswire January 22, 2024

Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery

GlobeNewswire December 20, 2023

Oculis Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema

GlobeNewswire December 18, 2023

Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNFα Licaminlimab (OCS-02) in Dry Eye Disease

GlobeNewswire December 7, 2023

Oculis Reports Q3 2023 Financial Results and Provides Company Update

GlobeNewswire November 15, 2023

Oculis to Present at Upcoming November Investor Conferences

GlobeNewswire November 8, 2023

Oculis to Present a Late-Breaking Abstract at the American Academy of Ophthalmology 2023 Annual Meeting on the Positive Stage 1 Results from Phase 3 DIAMOND Trial for Diabetic Macular Edema

GlobeNewswire November 1, 2023

Positive Phase 3 Stage 1 DIAMOND Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress

GlobeNewswire October 10, 2023

Oculis to Present a Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 DIAMOND Trial Results for Diabetic Macular Edema

GlobeNewswire October 5, 2023

Oculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Officer as it Enters Pre-Commercial Phase

GlobeNewswire September 11, 2023

Oculis to Present at Upcoming September Investor Conferences

GlobeNewswire August 30, 2023

Oculis Reports Q2 and First Half 2023 Financial Results and Provides Company Update

GlobeNewswire August 29, 2023

OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Both Primary Endpoints in Phase 3 OPTIMIZE Trial with a Once Daily Regimen for the Treatment of Inflammation and Pain Following Cataract Surgery

GlobeNewswire August 8, 2023

First Patient Enrolled in LEOPARD, an Investigator-Initiated Trial, with OCS-01 Eye Drops for the Treatment of Cystoid Macular Edema

GlobeNewswire August 2, 2023

Oculis Announces to Present at Upcoming August Investor Conferences

GlobeNewswire July 26, 2023